Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 584 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders sold 584 shares of the business’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $40.98, for a total transaction of $23,932.32. Following the transaction, the director now directly owns 12,009 shares of the company’s stock, valued at approximately $492,128.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ultragenyx Pharmaceutical Trading Down 1.8 %

Shares of NASDAQ:RARE opened at $40.21 on Thursday. The stock has a fifty day moving average of $41.08 and a 200-day moving average of $44.96. Ultragenyx Pharmaceutical Inc. has a one year low of $31.52 and a one year high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.31). The company had revenue of $108.83 million for the quarter, compared to analysts’ expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the company earned ($2.33) earnings per share. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Wedbush boosted their price objective on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a research report on Friday, May 31st. Royal Bank of Canada began coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $115.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 12th. Finally, Robert W. Baird upped their price target on shares of Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a research note on Friday, May 31st. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Ultragenyx Pharmaceutical during the first quarter valued at approximately $691,000. Farallon Capital Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $4,622,000. Artal Group S.A. purchased a new position in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $8,308,000. Bayesian Capital Management LP acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at $714,000. Finally, First Light Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 6.1% in the first quarter. First Light Asset Management LLC now owns 790,446 shares of the biopharmaceutical company’s stock valued at $36,906,000 after purchasing an additional 45,781 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.